Viagra for safer births? withdrawn trial leaves questions unanswered
NCT ID NCT06377098
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study planned to give sildenafil (the drug in Viagra) to women in labor in low-resource areas, aiming to reduce fetal distress and birth asphyxia. It was designed to test whether the drug could be safely given and to gather data for a larger trial. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sildenafil (the active ingredient in Viagra, given as 50 mg oral tablets during labor)
What this could lead to
If it had worked, this could have pointed toward a simple, low-cost way to reduce birth complications like oxygen deprivation in newborns.
What could go wrong
The trial was withdrawn before enrolling anyone, so no data exist. Even if conducted, it was a small pilot study, so results would be preliminary and might not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAPARTUM FETAL DISTRESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cameroon Baptist Convention Health Services
Douala, Cameroon
-
Egerton University/Nakuru County Referral Hospital
Nakuru, Kenya
-
University Teaching Hospital
Lusaka, Zambia